Lead Compound Sample Clauses

The Lead Compound clause defines the specific chemical compound that serves as the primary focus of a research, development, or licensing agreement. It typically identifies the compound by its chemical structure, name, or code, and may outline the rights and obligations of the parties regarding its development, modification, or commercialization. This clause ensures that both parties have a clear and mutual understanding of which compound is central to the agreement, thereby preventing disputes over scope and ownership.
POPULAR SAMPLE Copied 1 times
Lead Compound. A "Lead Compound" shall be deemed to have been -------------------- identified at such time as Schering, its Affiliates or Sublicensees initiates a program of medicinal chemistry optimization with respect to an Agreement Compound. Within thirty (30) days after the initiation of such a program, Schering shall notify Pharmacopeia thereof, which notification will include identification of the applicable Target(s) (in coded form only) and the general therapeutic area relevant to such Target.
View Source
Lead Compound. Subject to the terms and conditions of this Agreement (including the rest of this Section 8.2), Biogen Idec shall pay to Portola the milestone payments set forth below upon (i) [*][*] or [*][*]; or (ii) with respect to [*][*], [*][*] or [*][*]: [*] $[*] [*] $[*] [*] [*] $[*]; [*] $[*]; [*] $[*]; and [*] $[*]. [*] [*] [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. [*] $[*] [*] $[*] [*] $[*] [*] $[*] [*] $[*] [*] $[*] [*] $[*] [*] $[*] [*] $[*] [*] $[*]
View SourceView Similar (2)
Lead Compound. The term “
View SourceView Similar (2)
Lead Compound. As used herein "Lead Compound" shall mean a compound identified among the Hits as a compound suitable for Lead Optimization, with the aim to identify Potential CDs (as defined below) meeting the CD Nomination Criteria.
View SourceView Similar (2)
Lead Compound. Solvay will notify ArQule of the designation of any Licensed Compound or Derivative Compounds thereof as a lead compound that fulfills Solvay's primary criteria in a particular project (e.g., potency, selectivity, and bioavailability). Within 60 days of such designation, Solvay will provide ArQule with a copy of a revised time line of its research activities for that lead compound and will keep ArQule periodically informed of its progress under such schedule.
View SourceView Similar (2)
Lead Compound. Solvay Duphar will notify ArQule of the designation of any Active ArQule Compound or Derivatives thereof as a Lead Compound. Within 60 days of such designation, Solvay Duphar will provide ArQule with a copy of a revised time line of its research activities for that Lead Compound and will keep ArQule periodically informed of its progress under such schedule.
View Source
Lead Compound. A "Lead Compound" shall be deemed to have been -------------------- identified at such time as SPL, its Affiliates or Sublicensees initiates a program of medicinal chemistry optimization with respect to an Agreement Compound. Within thirty (30) days after the initiation of such a program, SPL shall notify Pharmacopeia thereof, which notification will include identification __________________ * CONFIDENTIAL TREATMENT REQUESTED of the applicable Target(s) (in coded form only) and the general therapeutic area relevant to such Target.
View Source
Lead Compound. Subject to the terms and conditions of this Agreement (including the rest of this Section 8.2), Biogen Idec shall pay to Portola the milestone payments set forth below upon (i) [*][*] or [*][*]; or (ii) with respect to [*][*], [*][*] or [*][*]: 1. Commencement of the first Phase II Clinical Trial for the first Major Indication (i.e., not for a Product in a Niche Indication) $23,000,000 [*] $[*] [*] [*] $[*]; [*] $[*]; [*] $[*]; and [*] $[*]. [*] [*] [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. [*] $[*] [*] $[*] [*] $[*] [*] $[*] [*] $[*] [*] $[*] [*] $[*] [*] $[*] [*] $[*] [*] $[*]
View Source
Lead Compound. The Parties acknowledge and agree that CVT 3146 is the lead development candidate ("Lead Compound"). CVT may replace the Lead Compound with [ * ] at any time during the Term by providing FHI with forty five (45) days written notice thereof, which notice shall include the reason(s) for making any such replacement. Upon FHI's receipt of such notice, FHI shall have forty five (45) days in which to notify CVT that: (a) CVT should proceed with the development of [ * ] as the Lead Compound under the terms and conditions of this Agreement; or (b) FHI will terminate this Agreement under Section 12.2 below; provided, however, that if FHI has not provided any written notice by the end of such forty five (45)-day period, FHI automatically shall be deemed to have elected clause (a). If such notice from FHI to CVT indicates that FHI desires for CVT to proceed with the development of [ * ] as the Lead Compound, the Management Committee will then promptly and expeditiously prepare a Development Program and Annual Plan and Budget for [ * ]. FHI shall not be responsible for any Development Costs other than for pre-clinical studies after the Effective Date in connection with [ * ], until the date that FHI notifies CVT that it accepts (or, as set forth above, is deemed to have accepted) development of [ * ] as the new Lead Compound. The Parties acknowledge and agree that while CVT 3146 is the Lead Compound, CVT shall have no responsibility to conduct in parallel development activities with respect to [ * ] other than pre-clinical studies after the Effective Date, unless the parties otherwise mutually agree. Once CVT has replaced CVT 3146 with [ * ] as the Lead Compound, FHI shall be free to develop CVT 3146 in the FHI Field at FHI's sole cost and expense.
View Source

Related to Lead Compound

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Licensed Product The term “Licensed Product” shall mean any product (a) the manufacture, use, importation, sale or offer for sale of which would, in the absence of the license granted by this Agreement, infringe a Valid Claim of any of the Licensed Patent Rights, or (b) that is comprised of, utilizes or incorporates Licensed Biological Materials, or (c) that is discovered, developed or made using a Licensed Process.

  • Human Leukocyte Antigen Testing This plan covers human leukocyte antigen testing for A, B, and DR antigens once per member per lifetime to establish a member’s bone marrow transplantation donor suitability in accordance with R.I. General Law §27-20-36. The testing must be performed in a facility that is: • accredited by the American Association of Blood Banks or its successors; and • licensed under the Clinical Laboratory Improvement Act as it may be amended from time to time. At the time of testing, the person being tested must complete and sign an informed consent form that also authorizes the results of the test to be used for participation in the National Marrow Donor program.

  • Research Program The term “

  • Research Collaboration Upon FibroGen’s request, the Parties will discuss conducting a research program funded by AstraZeneca and directed toward franchise enhancement and lifecycle management for HIF Compounds or other topics that the Parties determine relevant to the Products and the Field. Upon agreement on the terms of such research program, the Parties will enter into a separate agreement or amend this Agreement accordingly.